A two-day symposium on the assessment and treatment of end-organ damage in kidney and metabolic disease. Gubra scientist Mette Viberg Østergaard will give a talk.
- Gubra ApS and Silence Therapeutics plc collaborate to develop RNAi therapies against novel liver-directed targets from Gubra’s streaMLine platform
- Gubra launches NeuroPedia – a mouse brain atlas for virtual neuroscience
- Gubra and Bayer AG collaborate to develop next generation cardiorenal treatments
- Drug candidate from obesity collaboration between Gubra and Boehringer Ingelheim enters clinical phase 1 trial
- Annual results 2020: A thriving core business and razor-sharp biotech profile